KR20230122181A - 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 - Google Patents

중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 Download PDF

Info

Publication number
KR20230122181A
KR20230122181A KR1020237027157A KR20237027157A KR20230122181A KR 20230122181 A KR20230122181 A KR 20230122181A KR 1020237027157 A KR1020237027157 A KR 1020237027157A KR 20237027157 A KR20237027157 A KR 20237027157A KR 20230122181 A KR20230122181 A KR 20230122181A
Authority
KR
South Korea
Prior art keywords
mers
acid sequence
seq
spike
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237027157A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 비. 웨이너
카루피아 무투마니
니란잔 와이. 사르데자이
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실바니아
이노비오 파마수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실바니아, 이노비오 파마수티컬즈, 인크. filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실바니아
Publication of KR20230122181A publication Critical patent/KR20230122181A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/215Coronaviridae, e.g. avian infectious bronchitis virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237027157A 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신 Ceased KR20230122181A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361910153P 2013-11-29 2013-11-29
US61/910,153 2013-11-29
KR1020167015308A KR20160091350A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
PCT/US2014/067537 WO2015081155A1 (en) 2013-11-29 2014-11-26 Mers-cov vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015308A Division KR20160091350A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Publications (1)

Publication Number Publication Date
KR20230122181A true KR20230122181A (ko) 2023-08-22

Family

ID=53199622

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237027157A Ceased KR20230122181A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신
KR1020167015308A Ceased KR20160091350A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167015308A Ceased KR20160091350A (ko) 2013-11-29 2014-11-26 중동 호흡기 증후군 코로나바이러스(MERS-CoV) 백신

Country Status (10)

Country Link
US (5) US10016497B2 (https=)
EP (1) EP3074051A4 (https=)
JP (1) JP6412131B2 (https=)
KR (2) KR20230122181A (https=)
CN (2) CN105939730B (https=)
AU (1) AU2014354797C1 (https=)
CA (1) CA2932055A1 (https=)
IL (3) IL276210B2 (https=)
SA (1) SA516371223B1 (https=)
WO (1) WO2015081155A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134439A1 (en) 2013-03-01 2014-09-04 New York Blood Center, Inc. Immunogenic composition for mers coronavirus infection
WO2015081155A1 (en) * 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Mers-cov vaccine
US11103575B2 (en) 2014-02-28 2021-08-31 The New York Blood Center, Inc. Immunogenic composition for MERS coronavirus infection
EP3045181B1 (en) * 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
WO2017044507A2 (en) * 2015-09-08 2017-03-16 Sirnaomics, Inc. Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
CN106397549B (zh) * 2016-10-11 2019-08-06 中国疾病预防控制中心病毒病预防控制所 MERS-CoV特异性多肽及其应用
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
KR20180058206A (ko) * 2016-11-23 2018-05-31 에스케이케미칼 주식회사 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
EP3595676A4 (en) 2017-03-17 2021-05-05 Modernatx, Inc. RNA VACCINES AGAINST ZOONOSES
KR102017217B1 (ko) * 2017-10-19 2019-09-02 주식회사 엔케이맥스 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
JP2023511780A (ja) * 2020-02-25 2023-03-22 イノビオ ファーマシューティカルズ,インコーポレイティド コロナウイルスに対するワクチンおよび使用方法
CN111378785A (zh) * 2020-03-12 2020-07-07 仁宽(上海)生物科技有限公司 用于核酸诊断新型冠状病毒2019-nCov的假病毒标准品及其应用
US11559577B2 (en) 2020-03-31 2023-01-24 Engimata, Inc. Immunogenic composition forming a vaccine, and a method for its manufacture
WO2021225344A1 (ko) * 2020-05-08 2021-11-11 한림대학교 산학협력단 코로나 바이러스 억제용 펩타이드 및 그 용도
US20230226170A1 (en) * 2020-05-12 2023-07-20 Greffex, Inc. Engineering coronavirus spike proteins as vaccine antigens, their design and uses
US20230210981A1 (en) * 2020-06-09 2023-07-06 The Wistar Institute Of Anatomy And Biology Coronavirus disease 2019 (covid-19) combination vaccine
EP4178545A4 (en) * 2020-07-10 2024-08-07 Engimata, Inc IMMUNOGENIC COMPOSITION FORMING A VACCINE AND METHOD OF MANUFACTURE THEREOF
US20230270844A1 (en) * 2020-07-22 2023-08-31 Greffex, Inc. Multivalent beta-coronavirus vaccines, their designs and uses
JPWO2022025029A1 (https=) * 2020-07-27 2022-02-03
UY39378A (es) * 2020-08-14 2022-01-31 Univ Wuerzburg J Maximilians Vacuna de salmonella para el tratamiento de coronavirus
US20240016919A1 (en) * 2020-08-25 2024-01-18 The Wistar Institute Of Anatomy And Biology INTRADERMAL MERS-CoV VACCINE
US20230349889A1 (en) * 2020-09-10 2023-11-02 The Council Of The Queensland Institute Of Medical Research Methods of Determining Immune Response
AU2021340715A1 (en) * 2020-09-11 2023-04-27 Mark J. Cantwell Enhancing immunity using chimeric cd40 ligand and coronavirus vaccine
US20220370598A1 (en) * 2021-05-05 2022-11-24 Inovio Pharmaceuticals, Inc. Vaccines Against Coronavirus and Methods of Use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US3805783A (en) 1971-02-12 1974-04-23 A Ismach Hand powered hypodermic jet injector gun
US4342310A (en) 1980-07-08 1982-08-03 Istvan Lindmayer Hydro-pneumatic jet injector
US4447223A (en) 1982-04-16 1984-05-08 Cct Associates Medicament implant applicator
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5505697A (en) 1994-01-14 1996-04-09 Mckinnon, Jr.; Charles N. Electrically powered jet injector
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
JP2002520101A (ja) 1998-07-13 2002-07-09 ジェネトロニクス、インコーポレーテッド 電気的に補助される化粧用薬剤の局部送達法および装置
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US6520950B1 (en) 1999-05-10 2003-02-18 Genetronics, Inc. Method of electroporation-enhanced delivery of active agents
US7171264B1 (en) 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
DK1526175T4 (da) * 2003-08-18 2021-04-26 Amsterdam Inst Of Viral Genomics B V Coronavirus, nukleinsyre, protein og fremgangsmåder til generering af vaccine, lægemidler og diagnostik
CN101098710A (zh) * 2004-06-02 2008-01-02 纽约血液中心 产生高度有效抗体的sars疫苗和方法
AU2005250477A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
US7553944B2 (en) * 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
NO2324113T3 (https=) * 2008-08-08 2018-07-28
CA2819552C (en) * 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
BR112014013745B1 (pt) 2011-12-09 2022-06-14 Institut Pasteur Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex
US9555094B2 (en) * 2012-07-23 2017-01-31 The Institute Of Biological Resources Isolated nucleic acid for the production of a vaccine against virus
BR112016006122B1 (pt) 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
WO2015081155A1 (en) * 2013-11-29 2015-06-04 The Trustees Of The University Of Pennsylvania Mers-cov vaccine

Also Published As

Publication number Publication date
AU2014354797B2 (en) 2017-10-26
EP3074051A4 (en) 2017-04-12
US11135284B2 (en) 2021-10-05
US10548971B2 (en) 2020-02-04
AU2014354797C1 (en) 2018-02-01
IL245903A0 (en) 2016-07-31
SA516371223B1 (ar) 2023-01-31
KR20160091350A (ko) 2016-08-02
IL276210A (en) 2020-09-30
IL276210B1 (en) 2023-09-01
US10016497B2 (en) 2018-07-10
WO2015081155A1 (en) 2015-06-04
CN105939730A (zh) 2016-09-14
AU2014354797A1 (en) 2016-07-07
IL305392A (en) 2023-10-01
US20210401972A1 (en) 2021-12-30
EP3074051A1 (en) 2016-10-05
IL276210B2 (en) 2024-01-01
US20190022213A1 (en) 2019-01-24
CN105939730B (zh) 2020-09-11
US20170258893A1 (en) 2017-09-14
IL245903B (en) 2020-08-31
JP6412131B2 (ja) 2018-10-24
US20240123056A1 (en) 2024-04-18
US11801298B2 (en) 2023-10-31
US20200222527A1 (en) 2020-07-16
CA2932055A1 (en) 2015-06-04
CN112057613A (zh) 2020-12-11
JP2016539946A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
US11801298B2 (en) MERS-CoV vaccine
US11027011B2 (en) Vaccines with biomolecular adjuvants
US12268735B2 (en) Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
KR102395493B1 (ko) Hiv-1 env dna 백신과 단백질 부스터
IL302645A (en) Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine
KR20220149907A (ko) 환자의 예방접종 및 치료를 위한 포와산(powassan) 바이러스 항원 및 관련 조성물, 및 그의 용도
HK40042641A (en) Mers-cov vaccine
HK1228285B (zh) Mers-cov疫苗
TW202400635A (zh) 針對sars-cov-2變異體之免疫原性組合物及其使用方法
HK1228285A1 (en) Mers-cov vaccine

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230809

Application number text: 1020167015308

Filing date: 20160609

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240426

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20240628

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D